MOMaureen O’Keeffe-Rosetti

Maureen O’Keeffe-Rosetti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maureen O’Keeffe-Rosetti has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction to: Early Colorectal Cancer Detected by Machine Learning Model Using Gender, Age, and Complete Blood Count Data

    by Mark C. Hornbrook, Ran Goshen, Eran Choman, Maureen O’kEeffe-Rosetti, Yaron Kinar, Elizabeth G. Liles, Kristal C. Rust

    The article Early Colorectal Cancer Detected by Machine Learning Model Using Gender, Age, and Complete Blood Count Data, written by Mark C. Hornbrook, Ran Goshen, Eran Choman, Maureen O’Keeffe-Rosetti


  • Open Access

    Early Colorectal Cancer Detected by Machine Learning Model Using Gender, Age, and Complete Blood Count Data

    by Mark C. Hornbrook, Ran Goshen, Eran Choman, Maureen O’kEeffe-Rosetti, Yaron Kinar, Elizabeth G. Liles, Kristal C. Rust

    Background Machine learning tools identify patients with blood counts indicating greater likelihood of colorectal cancer and warranting colonoscopy referral. Aims To validate a machine learning colorectal cancer detection model on a US community-based insured adult population. Methods Eligible colorectal cancer cases (439 females, 461 males) with complete blood counts before diagnosis were identified from Kaiser Permanente Northwest Region’s Tumor Registry. Control patients (n = 9108) were randomly selected from KPNW’s population who had no cancers, received at ≥1 blood count, had continuous enrollment from 180 days prior to the blood count through 24 months after the count, and were aged 40–89. For each control, one blood count was randomly selected as the pseudo-colorectal cancer diagnosis date for matching to cases, and assigned a “calendar year” based on the count date. For each calendar year, 18 controls were randomly selected to match the general enrollment’s 10-year age groups and lengths of continuous enrollment. Prediction performance was evaluated by area under the curve, specificity, and odds ratios. Results Area under the receiver operating characteristics curve for detecting colorectal cancer was 0.80 ± 0.01. At 99% specificity, the odds ratio for association of a high-risk detection score with colorectal cancer was 34.7 (95% CI 28.9–40.4). The detection model had the highest accuracy in identifying right-sided colorectal cancers. Conclusions ColonFlag® identifies individuals with tenfold higher risk of undiagnosed colorectal cancer at curable stages (0/I/II), flags colorectal tumors 180–360 days prior to usual clinical diagnosis, and is more accurate at identifying right-sided (compared to left-sided) colorectal cancers.


  • Open Access

    Diffusion of Intraperitoneal Chemotherapy in Women with Advanced Ovarian Cancer in Community Settings 2003–2008: The Effect of the NCI Clinical Recommendation

    by Erin J. Aiello Bowles, Karen J. Wernli, Heidi J. Gray, Andy Bogart, Thomas Delate, Maureen O’Keeffe-Rosetti, Larissa Nekhlyudov, Elizabeth Trice Loggers

    Purpose: A 2006 National Cancer Institute (NCI) clinical announcement recommended the use of combined intravenous (IV) and intraperitoneal (IP) chemotherapy over IV chemotherapy alone for women with International Federation of Gynecology and Obstetrics (FIGO) stage 3 optimally debulked ovarian cancer due to significant survival benefit demonstrated in multiple randomized clinical trials. We examined uptake of IP chemotherapy in community practice before and after this recommendation. Methods: We identified 288 women with FIGO stage 2 or greater incident ovarian cancer diagnosed from 2003 to 2008 at three integrated delivery systems in the US. Administrative health plan data were used to determine patient characteristics and receipt of IV and IP chemotherapy within 12 months of diagnosis. We compared characteristics of women receiving IV chemotherapy alone versus IP chemotherapy (with or without IV chemotherapy) and assessed temporal trends in IP chemotherapy use. Results: Overall 12.5% (n=36) of women received IP chemotherapy during the study period. IP chemotherapy use was nonexistent between 2003 and 2005. Use of IP chemotherapy occurred among 26.9% of women diagnosed in 2006 and plateaued at 20.4% of women diagnosed in 2008. IP recipients were younger (mean age 55.9 vs 63.5 years, p= Conclusions: Use of IP chemotherapy for newly diagnosed advanced stage ovarian cancer patients was uncommon in this community setting. Future research should identify potential patient, physician, and system barriers and facilitators to using IP chemotherapy in this setting.


  • Open Access

    A Standardized Relative Resource Cost Model for Medical Care: Application to Cancer Control Programs

    by Maureen C. O’keeffe-Rosetti, Mark C. Hornbrook, Paul A. Fishman, Debra P. Ritzwoller, Erin M. Keast, Jenny Staab, Jennifer Elston Lafata, Ramzi Salloum

    Medicare data represent 75% of aged and permanently disabled Medicare beneficiaries enrolled in the fee-for-service (FFS) indemnity option, but the data omit 25% of beneficiaries enrolled in Medicare Advantage health maintenance organizations (HMOs). Little research has examined how longitudinal patterns of utilization differ between HMOs and FFS. The Burden of Cancer Study developed and implemented an algorithm to assign standardized relative costs to HMO and Medicare FFS data consistently across time and place. Medicare uses 15 payment systems to reimburse FFS providers for covered services. The standardized relative resource cost algorithm (SRRCA) adapts these various payment systems to utilization data. We describe the rationale for modifications to the Medicare payment systems and discuss the implications of these modifications. We applied the SRRCA to data from four HMO sites and the linked Surveillance, Epidemiology, and End Results–Medicare data. Some modifications to Medicare payment systems were required, because data elements needed to categorize utilization were missing from both data sources. For example, data were not available to create episodes for home health services received, so we assigned costs per visit based on visit type (nurse, therapist, and aide). For inpatient utilization, we modified Medicare’s payment algorithm by changing it from a flat payment per diagnosis-related group to daily rates for diagnosis-related groups to differentiate shorter versus longer stays. The SRRCA can be used in multiple managed care plans and across multiple FFS delivery systems within the United States to create consistent relative cost data for economic analyses. Prior to international use of the SRRCA, data need to be standardized.


  • Open Access

    Adherence to surveillance care guidelines after breast and colorectal cancer treatment with curative intent

    by Ramzi G. Salloum, Mark C. Hornbrook, Paul A. Fishman, Debra P. Ritzwoller, Maureen C. O'KEeffe Rossetti, Jennifer Elston Lafata

    BACKGROUND: Evidence‐based guidelines recommend routine surveillance, including office visits and testing, to detect new and recurrent disease among survivors of breast and colorectal cancer. The extent to which surveillance practice is consistent with guideline recommendations or may vary by age is not known.METHODS: Cohorts of adult patients diagnosed with breast (n = 6205) and colorectal (n = 2297) cancer between 2000 and 2008 and treated with curative intent in 4 geographically diverse managed care environments were identified via tumor registries. Kaplan‐Meier estimates were used to describe time to initial and subsequent receipt of surveillance services. Cox proportional hazards models evaluated the relation between patient characteristics and receipt of metastatic screening.RESULTS: Within 18 months of treatment, 87.2% of breast cancer survivors received recommended mammograms, with significantly higher rates noted for patients aged 50 years to 65 years. Among survivors of colorectal cancer, only 55.0% received recommended colon examinations, with significantly lower rates for those aged ≥ 75 years. The majority of breast (64.7%) and colorectal (73.3%) cancer survivors received nonrecommended metastatic disease testing. In patients with breast cancer, factors associated with metastatic disease testing include white race (hazards ratio [HR], 1.13), comorbidities (HR, 1.17), and younger age (HR, 1.13; 1.15; 1.13 for age groups: <50, 50–64, and 65–74 respectively). In those with colorectal cancer, these factors included younger age (HR, 1.31; 1.25 for age groups: <50 and 50–64 respectively) and comorbidities (HR, 1.10).CONCLUSIONS: Among an insured population, wide variation regarding the use of surveillance care was found by age and relative to guideline recommendations. Breast cancer survivors were found to have high rates of both guideline‐recommended recurrence testing and non–guideline‐recommended metastatic testing. Only approximately 50% of colorectal cancer survivors received recommended tests but greater than 67% received metastatic testing. Cancer 2012. © 2012 American Cancer Society.


    • 1 January 2002
      • Vol. 8  (1) , 45-53

    Issues in pooling administrative data for economic evaluation.

    by Richard T Meenan, Michael J Goodman, Paul A Fishman, Mark C Hornbrook, Maureen C O'Keeffe-Rosetti, Donald J Bachman

    Managed care, in particular the health maintenance organization (HMO), now dominates US healthcare delivery, and economic evaluation is receiving increasing attention as a management tool that can be tailored to its perceived business needs. This encourages use of HMO administrative data as an efficient source of resource utilization and cost measures. Use of administrative data coincides with growing research interest in multisite analyses that increase external validity. The best alternative to a nationally representative data set is to pool administrative data from multiple sites within one database. However, pooling administrative data is problematic because HMO data sources reflect differences in systems of care, costing, and coding. This paper describes issues inherent in the pooling of HMO administrative cost data for use in multisite economic evaluations. We describe the attributes of administrative data that are relevant to costing and discuss their implications for multisite economic evaluations. We then briefly describe our experience with pooling multisite cost data, discuss lessons learned, and offer suggestions for researchers working with such data, followed by concluding comments. Multisite administrative data provide unique opportunities to conduct population-based clinical and economic research.